Shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) have been assigned an average rating of “Hold” from the six brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $19.50.
Several research analysts have commented on TAK shares. ValuEngine downgraded Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. Jefferies Financial Group began coverage on Takeda Pharmaceutical in a research report on Tuesday, September 24th. They issued a “buy” rating for the company. Zacks Investment Research raised Takeda Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, November 5th. Daiwa Capital Markets downgraded shares of Takeda Pharmaceutical from an “outperform” rating to a “neutral” rating in a research note on Thursday, August 15th. Finally, Cowen started coverage on shares of Takeda Pharmaceutical in a research report on Friday, November 1st. They set a “market perform” rating and a $19.50 target price on the stock.
Shares of NYSE:TAK traded down $0.18 during midday trading on Tuesday, hitting $20.38. The company’s stock had a trading volume of 1,217,500 shares, compared to its average volume of 2,366,127. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.94 and a current ratio of 1.45. The stock’s 50 day simple moving average is $19.16 and its 200 day simple moving average is $17.78. The stock has a market capitalization of $63.28 billion, a price-to-earnings ratio of 39.96 and a beta of 0.76. Takeda Pharmaceutical has a fifty-two week low of $15.50 and a fifty-two week high of $21.61.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in TAK. Checchi Capital Advisers LLC increased its stake in Takeda Pharmaceutical by 3.9% during the third quarter. Checchi Capital Advisers LLC now owns 14,477 shares of the company’s stock valued at $249,000 after acquiring an additional 547 shares during the period. Coastal Investment Advisors Inc. grew its holdings in shares of Takeda Pharmaceutical by 59.8% during the 2nd quarter. Coastal Investment Advisors Inc. now owns 1,718 shares of the company’s stock worth $32,000 after purchasing an additional 643 shares in the last quarter. Stephens Inc. AR grew its holdings in shares of Takeda Pharmaceutical by 6.7% during the 3rd quarter. Stephens Inc. AR now owns 11,704 shares of the company’s stock worth $201,000 after purchasing an additional 732 shares in the last quarter. HighTower Advisors LLC increased its position in shares of Takeda Pharmaceutical by 3.2% during the second quarter. HighTower Advisors LLC now owns 29,939 shares of the company’s stock valued at $534,000 after purchasing an additional 919 shares during the period. Finally, SRS Capital Advisors Inc. increased its position in shares of Takeda Pharmaceutical by 83.3% during the third quarter. SRS Capital Advisors Inc. now owns 2,200 shares of the company’s stock valued at $38,000 after purchasing an additional 1,000 shares during the period. Institutional investors and hedge funds own 4.58% of the company’s stock.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Featured Article: Monthly Dividend Stocks Can Provide Solid Income
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.